在哥本哈根进行的一项临床试验中，诺和诺德（Novo Nordisk）的减肥药物疗效未能超越礼来（Eli Lilly）的同类产品。受此消息提振，礼来股价在盘前交易时段应声上涨2.1%。该结果进一步加剧了全球两大制药巨头在利润丰厚的减肥药市场竞争的白热化程度。
在哥本哈根进行的一项临床试验中，诺和诺德（Novo Nordisk）的减肥药物疗效未能超越礼来（Eli Lilly）的同类产品。受此消息提振，礼来股价在盘前交易时段应声上涨2.1%。该结果进一步加剧了全球两大制药巨头在利润丰厚的减肥药市场竞争的白热化程度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.